Edgar Filing: Silva Paul M - Form 4

Silva Paul M Form 4	ĺ										
May 06, 201		S SECUR		- 3235-0287							
Washington, D.C. 20549Check this box if no longer subject to Section 16. 									Expires: January 3 Expires: 200 Estimated average burden hours per response 0.		
(Print or Type I	Responses)										
1. Name and Address of Reporting Person <u>*</u> Silva Paul M			2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) C/O VERTI PHARMAC INCORPOF ST.	3. Date of Earliest Transaction (Month/Day/Year) 05/02/2013					Director 10% Owner XOfficer (give titleOther (specify below) SVP & Corp Controller					
(Street) 4.				ndment, Da hth/Day/Year	-	1		6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative	Secur	ities Acq	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date 2A. Deen (Month/Day/Year) Execution any (Month/D			Transaction(A) or Code (Instr.) (Instr. 8)		(A) or	d of (D) 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock	05/02/2013			Code V M	Amount 1,125	(D) A	Price \$ 37.86	12,875	D		
Common Stock	05/02/2013			S <u>(1)</u>	700	D		12,175	D		
Common Stock	05/02/2013			S <u>(1)</u>	425	D	\$ 77.59 (3) (4)	11,750	D		

Edgar Filing: Silva Paul M - Form 4

Common Stock	05/03/2013	М	937	А	\$ 38.8	12,687	D	
Common Stock	05/03/2013	S <u>(1)</u>	637	D	\$ 75.76 (3) (5)	12,050	D	
Common Stock	05/03/2013	S <u>(1)</u>	200	D	\$ 76.66 (3) (6)	11,850	D	
Common Stock	05/03/2013	S <u>(1)</u>	100	D	\$ 78.12	11,750	D	
Common Stock						169	I	401(k)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02) required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number on f Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. H Dei Sec (In:
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 37.86	05/02/2013		М	1,125	(7)	02/01/2022	Common Stock	1,125	
Stock Option (right to buy)	\$ 38.8	05/03/2013		М	937	<u>(8)</u>	02/02/2021	Common Stock	937	

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer

Other

SVP & Corp Controller

Silva Paul M C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST. CAMBRIDGE, MA 02139

Signatures

Kenneth L. Horton, Attorney-In-Fact

05/06/2013

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
- (2) Open market sales reported on this line occurred at a weighted average price of \$77.17 (range \$76.48 to \$77.41).
- (3) Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- (4) Open market sales reported on this line occurred at a weighted average price of \$77.59 (range \$77.49 to \$77.72).
- (5) Open market sales reported on this line occurred at a weighted average price of \$75.76 (range \$75.42 to \$76.21).
- (6) Open market sales reported on this line occurred at a weighted average price of \$76.66 (range \$76.47 to \$76.85).
- (7) The option vests in 16 quarterly installments beginning on 02/02/2012.
- (8) The option vests in 16 quarterly installments beginning on 02/03/2011.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.